# Novartis secures new radioligand in $900M deal as competition strengthens

> **Open Intelligence Dossier** · First detected: 2026-09-22 21:20 UTC · Category: Business

## Executive Summary
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.

## Intelligence Brief
Recent business reporting highlights a significant transaction involving Novartis and BoomRay, centered on the acquisition of a new radioligand asset. According to coverage from European Biotechnology Magazine, AllSci, Pharmaceutical Executive, FirstWord Pharma, and Fierce Biotech, the agreement involves a financial figure of $900 million. The asset originated in China and is currently at the preclinical stage of development. This move represents a strategic addition to the acquiring company&amp;#039;s existing therapeutic pipeline within the radioligand therapy sector. Specific details regarding the arrangement have been outlined across multiple specialized industry publications.


Outlets such as Pharmaceutical Executive and European Biotechnology Magazine detail that the deal takes the form of a global license agreement. AllSci emphasizes the China-origin status of the RLT asset, while Fierce Biotech notes that the transaction occurs within an environment of strengthening competition in the pharmaceutical market. FirstWord Pharma characterizes the agreement as the latest bet by Novartis in the radioligand space. Context provided within the ongoing reporting indicates that this transaction builds upon broader market activities surrounding radioligand therapeutics. The coverage does not yet specify detailed clinical trial timelines, regulatory milestones, or the precise therapeutic targets of the BoomRay asset beyond its classification as a preclinical radioligand.


Industry observers following the developments note that the sector is experiencing heightened competitive pressures, prompting major pharmaceutical firms to secure early-stage assets through high-value licensing agreements. Future updates will depend on official announcements from the involved companies regarding development milestones and regulatory filings. Stakeholders monitoring the space will be watching for subsequent disclosures from Novartis and BoomRay concerning the advancement of the preclinical asset toward clinical trials. Coverage does not yet specify further financial terms beyond the initial $900 million figure or indicate when clinical development activities might officially commence.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| European Biotechnology Magazine | Novartis licenses BoomRay radioligand asset for $900M | [Source Link](https://news.google.com/rss/articles/CBMiogFBVV95cUxOMzViWVFnMFJJcWdsSm9ySGRkcEVsOG9vMXFRWkhUdGlPM3lfeEtDRzMwZlB2SGZXWDRTaFJ5VDBJdDZJZUpPWERUSHNqNnZ1R19WUjhCZ24xb3E5OGRNR3JFQjRHa2p0LTYwVnhxMC1uaE1rcjJGWlVEOGxoS1plODBRN05KSnB2UlF4RWJWS1YtdGRnSVRNYldkS2hzbmY4eGc?oc=5) |
| AllSci | - Novartis adds China-origin RLT asset through BoomRay licensing deal | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNWlZ5M1F2UW9YYmxyYW8ydHZxTlA1enV6ekwwR25PbXR3Y0phUnVOdEZxbFNFZjhUWVl2MkQ4bTRPcmFyaDd4aVlKS3VNbXNkVE5aMFQ5alFEM0ZQSGV1UHFQbmZxRm9uVDZUU3VydmFDVU10MDN3RnZzRWlPX3EzSlNxSFpPSFBpY2RkLUpmNzZ5aVRuOW4xdnhlaFFBUFE?oc=5) |
| Pharmaceutical Executive | Novartis & BoomRay Enter Global License Agreement for Preclinical Radioligand Asset | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxQS2p5eUVXTnZXSWE4VHN3N2ZRWHZCQW9DRDRRbmRFX0l1MGdkTUxIN0l0ZDdPcVJ2VG5OMjhuRHE2bjkzaWFYMmkxVGNhclRUWHZoR1FfWm1RWUw0UzVoZWVLNTZsZE4tWExUN0RoNzlvbVMzYzhZMWFPZjZBZi16ekFiUTFtN3lrelVDMkFCaTFYS2FEZlNZdExxaXBUVmIzRVlYMQ?oc=5) |
| FirstWord Pharma | Novartis makes latest radioligand bet with $900M BoomRay deal | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1kTkRlSTBRUG5aSGg0U2tKZDNLT0UyWWpMbU1UVXNCT1ZETTFETlVnQjhZcGU4REx4dmpnR2hlU1FkR3lxT0tPRk9kV0hVQnctaklV?oc=5) |
| Fierce Biotech | Novartis secures new radioligand in $900M deal as competition strengthens | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxOcDdCcmRCMm5lbzRWclRrYVVKT3lFY3IxNFN6eFN2MTcyOW1CbEVCdnJOWXQwcjhqcm5lM011S1lGVDIwWElLbUdsdTBxRUdtRG9udk4xZzBLR2toZkhsV1Iwc0VCakNCaXJBTHJVWG5KRmlEQVJOWjktdFdyWFFQLXZNa3RFNGM5QWxiOUJiQlRJVHhTZm01eGt0ZzMzVHlFcDVhN2VnRQ?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-22/novartis-secures-new-radioligand-in-900m-deal-as-competition-strengthens*
